SI21369A - Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega - Google Patents

Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega Download PDF

Info

Publication number
SI21369A
SI21369A SI200220013A SI200220013A SI21369A SI 21369 A SI21369 A SI 21369A SI 200220013 A SI200220013 A SI 200220013A SI 200220013 A SI200220013 A SI 200220013A SI 21369 A SI21369 A SI 21369A
Authority
SI
Slovenia
Prior art keywords
compound
hydrogen
compounds
host
geldanamycin
Prior art date
Application number
SI200220013A
Other languages
English (en)
Slovenian (sl)
Inventor
Kenneth M. SNADER
Rao B. Vishnuvajjala
Melinda G. Hollingshead
Edward A. SAUSVILLE
Original Assignee
The United States Of America, Represented By The Secretary,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, Represented By The Secretary, filed Critical The United States Of America, Represented By The Secretary,
Publication of SI21369A publication Critical patent/SI21369A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200220013A 2001-03-30 2002-03-28 Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega SI21369A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28007801P 2001-03-30 2001-03-30
PCT/US2002/010097 WO2002079167A1 (fr) 2001-03-30 2002-03-28 Derive de geldanamycine et procede de traitement du cancer a l'aide de celui-ci

Publications (1)

Publication Number Publication Date
SI21369A true SI21369A (sl) 2004-06-30

Family

ID=23071560

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200220013A SI21369A (sl) 2001-03-30 2002-03-28 Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega

Country Status (19)

Country Link
US (1) US6890917B2 (fr)
EP (1) EP1373215B1 (fr)
JP (1) JP4213472B2 (fr)
KR (1) KR100831133B1 (fr)
CN (1) CN1262542C (fr)
AT (1) ATE334119T1 (fr)
AU (1) AU2002307020B2 (fr)
CA (1) CA2430692C (fr)
CY (1) CY1107484T1 (fr)
DE (1) DE60213386T2 (fr)
DK (1) DK1373215T3 (fr)
ES (1) ES2268068T3 (fr)
IL (2) IL156122A0 (fr)
MX (1) MXPA03007856A (fr)
NZ (1) NZ526133A (fr)
PT (1) PT1373215E (fr)
SI (1) SI21369A (fr)
WO (1) WO2002079167A1 (fr)
ZA (1) ZA200304178B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
WO2005009345A2 (fr) 2003-06-13 2005-02-03 Kosan Biosciences, Inc. Composes de 2-desmethyl ansamycine
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
WO2005056531A1 (fr) * 2003-11-12 2005-06-23 Kosan Biosciences, Inc. Composes 11-o-methylgeldanamycine
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
ES2409351T3 (es) * 2003-12-23 2013-06-26 Infinity Discovery, Inc. Análogos de ansamicinas que contienen benzoquinona para el tratamiento de cáncer
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7259156B2 (en) 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
EP1863769A4 (fr) * 2005-03-11 2009-03-18 Univ Colorado Inhibiteurs hsp90, procedes de realisation et d'utilisation correspondants
KR20080007642A (ko) * 2005-04-29 2008-01-22 코산 바이오사이언시즈, 인코포레이티드 프로테아좀 억제제와 함께 17-ａａｇ 또는 17-ａｇ 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법
JP2008543941A (ja) * 2005-06-21 2008-12-04 インフィニティ・ディスカバリー・インコーポレイテッド アンサマイシン製剤およびその使用方法
WO2007059116A2 (fr) * 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Derives de geldanamycine et compositions pharmaceutiques associees
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
WO2007098229A2 (fr) * 2006-02-21 2007-08-30 Michigan State University Derives de la geldanamycine et leur procede d'utilisation
CN100519536C (zh) * 2006-03-21 2009-07-29 中国医学科学院医药生物技术研究所 一组连有核苷碱基的格尔德霉素衍生物
WO2007130403A2 (fr) * 2006-05-02 2007-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education RÉGULATION DE PROTÉINE ApoB PAR LES PROTÉINES Hspl 10, COMPOSITIONS ET PROCÉDÉ S'Y RAPPORTANT
KR100796637B1 (ko) * 2006-09-29 2008-01-22 한국생명공학연구원 젤다나마이신 유도체, 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 및치료제
CN100500668C (zh) * 2006-12-19 2009-06-17 中国人民解放军军事医学科学院毒物药物研究所 格尔德霉素衍生物及其制备方法和制备药物的用途
EP2121957A4 (fr) * 2007-01-26 2010-11-10 Kosan Biosciences Inc Macrolactames obtenus par biosynthèse modifiée
US8303960B2 (en) * 2007-02-27 2012-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
WO2008116216A1 (fr) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions et procédés permettant d'inhiber les métastases
BRPI0810835A2 (pt) * 2007-04-12 2015-06-16 Infinity Discovery Inc Formulações de hidroquinona ansamicina
EP2190291B1 (fr) 2007-08-23 2015-10-14 The Regents of The University of Colorado, A Body Corporate Inhibiteurs de hsp90 avec toxicité modifiée
EP2200653A2 (fr) 2007-09-10 2010-06-30 University of Massachusetts Agents antitumoraux ciblant les mitochondries
US20090186039A1 (en) * 2008-01-18 2009-07-23 Jang Sung-Key Novel use of grp 94 in virus infection
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
EP2348845A4 (fr) 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc Compositions d'ansamycine hydroquinone
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
EP2471918A4 (fr) 2009-09-29 2013-06-05 Takeda Pharmaceutical Méthode de criblage
CN102030764B (zh) * 2010-11-12 2012-07-04 中国医学科学院医药生物技术研究所 4，5双氢噻嗪酮格尔德霉素及其制备方法
WO2012082765A2 (fr) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Méthodes pour réduire le poids corporel et traiter le diabète
CN102603635B (zh) * 2011-01-21 2016-08-03 杭州华东医药集团生物工程研究所有限公司 格尔德霉素衍生物及其制备方法和用途
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
WO2013074695A1 (fr) 2011-11-14 2013-05-23 The Regents Of The University Of Colorado, A Body Corporate Inhibiteurs de hsp90 ayant une toxicité modifiée
CN102552150B (zh) * 2012-03-02 2013-10-30 首都医科大学 一种格尔德霉素脂质体的制备及应用
WO2018160772A1 (fr) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Procédé de traitement de l'obésité, de la résistance à l'insuline, d'une stéatose hépatique non alcoolique comprenant une stéatohépatite non alcoolique

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS55111469A (en) 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
JPS55111470A (en) 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Geldanamycin derivative, its preparation, antitumor drug comprising it as active ingredient
JPS55111419A (en) 1979-02-20 1980-08-28 Kaken Pharmaceut Co Ltd Antitumorigenic agent
JP2794342B2 (ja) * 1993-06-29 1998-09-03 ファイザー・インク． 抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体
ATE202571T1 (de) 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
CA2218523A1 (fr) 1995-05-02 1996-11-07 William J. Welch Induction de la thermotolerance a l'aide d'ansamycines benzoquinonoides
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5948814A (en) 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
US5952175A (en) 1997-10-09 1999-09-14 Incyte Pharmaceuticals, Inc. DNA encoding a human progesterone receptor complex p23-like protein
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration

Also Published As

Publication number Publication date
ZA200304178B (en) 2004-02-17
CN1262542C (zh) 2006-07-05
US20040053909A1 (en) 2004-03-18
CY1107484T1 (el) 2013-03-13
PT1373215E (pt) 2006-12-29
CN1484639A (zh) 2004-03-24
EP1373215A1 (fr) 2004-01-02
AU2002307020B2 (en) 2007-06-28
US6890917B2 (en) 2005-05-10
EP1373215B1 (fr) 2006-07-26
JP2004519514A (ja) 2004-07-02
CA2430692A1 (fr) 2002-10-10
JP4213472B2 (ja) 2009-01-21
ATE334119T1 (de) 2006-08-15
DK1373215T3 (da) 2006-11-13
IL156122A0 (en) 2003-12-23
DE60213386T2 (de) 2006-11-23
DE60213386D1 (de) 2006-09-07
KR20040023581A (ko) 2004-03-18
KR100831133B1 (ko) 2008-05-20
WO2002079167A1 (fr) 2002-10-10
IL156122A (en) 2010-11-30
ES2268068T3 (es) 2007-03-16
MXPA03007856A (es) 2003-12-04
NZ526133A (en) 2005-08-26
CA2430692C (fr) 2011-05-31

Similar Documents

Publication Publication Date Title
SI21369A (sl) Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega
AU2002307020A1 (en) Geldanamycin derivative and method of treating cancer using same
JP5838157B2 (ja) Ｈｄａｃ阻害剤およびそれを用いる治療法
KR20210018291A (ko) 항암 핵 호르몬 수용체-표적화 화합물
JP2018521095A (ja) 変異イソクエン酸デヒドロゲナーゼｉｄｈ１ ｒ１３２ｈの阻害剤
AU2012249646A1 (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
CA2295640A1 (fr) Aroylpiperazines destinees a moduler l'activite sexuelle
WO2018204370A1 (fr) Antagonistes de cx3cr1 à petites molécules, et procédés les utilisant
WO2002036574A1 (fr) Derives de geldanamycine utiles dans le traitement du cancer
JP2002520369A (ja) 水溶性薬剤およびその製造方法
WO2011025805A1 (fr) Agents antitumoraux dérivés d'alkyl-indole-3-carbinol
JPH11506763A (ja) ニューモシスティス・カリニ肺炎の抑制方法及びそのために有効な化合物
WO2022006412A2 (fr) Conjugués d'inhibiteurs d'ampk et d'agents de dégradation de protac et utilisations associées
GB2592555A (en) Cancer
EP0831811B1 (fr) Carbazoles dans le traitement d'infections microbiennes
CN113710660B (zh) Dot1l降解剂及其用途
WO2013138600A1 (fr) Composés radioprotecteurs
EA039778B1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
KR20130130802A (ko) 보르트만닌 유사체의 결정질 형태의 조성물 및 이의 사용 방법
KR100983318B1 (ko) 메조-비스(오쏘-하이드록시페닐)비스(오쏘-하이드록시)살렌의 항암제로서의 용도
WO2021046178A1 (fr) Composés et méthodes de traitement du cancer
WO2021046220A1 (fr) Composés et méthodes de traitement du cancer
AU2022421214A1 (en) Compounds for treatment of cancer
EP3263567A1 (fr) Pyrazoles substitués avec une carboxamide et tri(hétéro)aryle-pyrazoles pour utilisation dans le traitement et/ou prévention des maladies cariovasculaires et/ou leurs comorbidités
WO2004037978A2 (fr) Methodes permettant de reduire l'activite d'une proteine kit mutante et methodes permettant de reduire la concentration d'une proteine kit mutante

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20120405